7Q9I
Beta-43 fab in complex with SARS-CoV-2 beta-Spike glycoprotein
Summary for 7Q9I
| Entry DOI | 10.2210/pdb7q9i/pdb |
| Related | 4Q0I 7Q6E |
| EMDB information | 13857 13870 |
| Descriptor | Spike glycoprotein, Beta-43 heavy chain, Beta-43 light chain, ... (5 entities in total) |
| Functional Keywords | sars-cov2, spike, glycoprotein, antibody, fab, b.1.135, beta variant, complex, neutralising, convalescent sera, viral protein/immune system, viral protein-immune system complex |
| Biological source | Severe acute respiratory syndrome coronavirus 2 More |
| Total number of polymer chains | 9 |
| Total formula weight | 580532.71 |
| Authors | Duyvesteyn, H.M.E.,Ren, J.,Stuart, D.I. (deposition date: 2021-11-12, release date: 2021-12-15, Last modification date: 2024-10-09) |
| Primary citation | Liu, C.,Zhou, D.,Nutalai, R.,Duyvesteyn, H.M.E.,Tuekprakhon, A.,Ginn, H.M.,Dejnirattisai, W.,Supasa, P.,Mentzer, A.J.,Wang, B.,Case, J.B.,Zhao, Y.,Skelly, D.T.,Chen, R.E.,Johnson, S.A.,Ritter, T.G.,Mason, C.,Malik, T.,Temperton, N.,Paterson, N.G.,Williams, M.A.,Hall, D.R.,Clare, D.K.,Howe, A.,Goulder, P.J.R.,Fry, E.E.,Diamond, M.S.,Mongkolsapaya, J.,Ren, J.,Stuart, D.I.,Screaton, G.R. The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants. Cell Host Microbe, 30:53-, 2022 Cited by PubMed Abstract: Alpha-B.1.1.7, Beta-B.1.351, Gamma-P.1, and Delta-B.1.617.2 variants of SARS-CoV-2 express multiple mutations in the spike protein (S). These may alter the antigenic structure of S, causing escape from natural or vaccine-induced immunity. Beta is particularly difficult to neutralize using serum induced by early pandemic SARS-CoV-2 strains and is most antigenically separated from Delta. To understand this, we generated 674 mAbs from Beta-infected individuals and performed a detailed structure-function analysis of the 27 most potent mAbs: one binding the spike N-terminal domain (NTD), the rest the receptor-binding domain (RBD). Two of these RBD-binding mAbs recognize a neutralizing epitope conserved between SARS-CoV-1 and -2, while 18 target mutated residues in Beta: K417N, E484K, and N501Y. There is a major response to N501Y, including a public IgVH4-39 sequence, with E484K and K417N also targeted. Recognition of these key residues underscores why serum from Beta cases poorly neutralizes early pandemic and Delta viruses. PubMed: 34921776DOI: 10.1016/j.chom.2021.11.013 PDB entries with the same primary citation |
| Experimental method | ELECTRON MICROSCOPY (4.9 Å) |
Structure validation
Download full validation report
